A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension

Trial Profile

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia; Hypertension
  • Focus Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Aug 2015 Esperion Therapeutics expects to hold an end-of-phase II meeting with the US FDA for bempedoic acid in the first half of August 2015, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top